Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 8 484 / https://doi.org/10.3332/ecancer.2014.484

Clinical Study

How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients

Purpose: Elderly patients (65 or older) with cervical cancer often receive suboptimal radio-chemotherapy. Intensity-modulated radiotherapy (IMRT) may improve tolerance to treatment in this setting. This study was designed to compare the treatment-related toxicities and compliance with treatment in patients of cervical cancer treated definitively with RapidArc IMRT in our institute.

Methods and materials: The treatment records of all patients treated with RapidArc IMRT between April 2012 and April 2014 were reviewed, retrospectively. Prospectively collected data regarding treatment toxicity (CTCAE 4.0), treatment outcomes and parameters related to treatment compliance were compared amongst two age groups (< 65 and ≥ 65 years). The results of 66 patients were identified, of whom 23 were found to be ≥ 65 years age. All patients completed planned external beam radiotherapy. However, significantly fewer patients in the elderly group received concurrent chemoradiation (98% versus 65%, p < 0.001). Old age (median 75 years, IQR: 74–78 years) was the commonest cause for non-receipt of chemotherapy. Incidence of grade 3 haematological toxicities (26.7% versus 16.7%) and gastrointestinal toxicity (16.7% versus 13.3%) were not significantly different between the two groups. Other treatment-related toxicities, breaks, treatment duration and early outcomes were also not significantly different between the two age groups.

Conclusions: The use of IMRT did not result in excess toxicities in the elderly population and was associated with equivalent compliance to treatment. Concurrent chemoradiation can be safely combined in elderly patients with perfect organ function and performance status.

Keywords: uterine cervical neoplasms, aged, chemoradiation, intensity-modulated radiotherapy, toxicity

Loading Article Metrics ... Please wait

Related articles

Review: Conservative treatment for well-differentiated endometrial cancer: when and why it should be considered in young women

Abstract | Full Article | PDF Published: 17 Jan 2019 / https://doi.org/10.3332/ecancer.2019.892

Research: Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer

Abstract | Full Article | PDF Published: 15 Jan 2019 / https://doi.org/10.3332/ecancer.2019.891

Research: Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status

Abstract | Full Article | PDF Published: 08 Jan 2019 / https://doi.org/10.3332/ecancer.2019.890

Research: The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B

Abstract | Full Article | PDF Published: 21 Dec 2018 / https://doi.org/10.3332/ecancer.2018.889

Review: Spontaneous testicular tumor regression: case report and historical review

Abstract | Full Article | PDF | Spanish Published: 18 Dec 2018 / https://doi.org/10.3332/ecancer.2018.888



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation